Last edition
News about "Kyverna Therapeutics"
First Use of Kyverna KYV-101 in Patients with Progressive Multiple Sclerosis Published
Kyverna Therapeutics, Inc. has announced about a recent report published in Med that describes the first use of KYV-101, a fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, in two patients suffering from progressive multiple sclerosis (MS).
Kyverna Therapeutics | 30/03/2024 | By Manvi | 924
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members